Eltoukhy Helmy 4

What Happened

• Helmy Eltoukhy, Chief Executive Officer of Guardant Health (GH), reported open‑market dispositions totaling 100,000 shares on June 5, 2026. The sales were in multiple transactions at prices ranging roughly from $124.95 to $132.55, generating aggregate proceeds of approximately $12.63 million.
• Reported tranches (amounts and reported prices): 49,716 @ $125.57 ($6,242,788); 33,843 @ $126.33 ($4,275,261); 1,100 @ $127.02 ($139,727); 13,787 @ $128.25 ($1,768,198); 554 @ $130.21 ($72,134); 900 @ $131.78 ($118,606); 100 @ $132.55 ($13,255). All transactions are coded “S” (sale).

Key Details

• Transaction date: June 5, 2026 (filed on Form 4: June 8, 2026). Filing appears timely based on the Form 4 date.
• Prices: multiple trades with reported per‑share prices from about $124.95 up to $132.55; several entries include footnotes reporting weighted‑average prices and per‑trade price ranges (see footnotes F1–F6 in the filing).
• Shares sold: 100,000 total; proceeds ≈ $12,629,969.
• Shares owned after the transaction: Not specified in the supplied filing excerpt.
• Footnotes: Several footnotes state the shown prices are weighted averages and that the reporting person will provide full breakdowns of shares sold at each price upon request to the SEC or holders.
• Transaction code: S = Sale (disposition of shares), indicating these were sales rather than purchases or option exercises.

Context

• Sales by insiders can reflect many reasons (e.g., diversification, taxes, pre‑arranged plans) and are not, by themselves, a definitive signal about company prospects. The filing here documents open‑market/ private sales; no 10b5‑1 plan or other instruction was disclosed in the provided excerpt.
• For retail investors: note the trade size and timing, but avoid reading these sales alone as a buy/sell endorsement — combine with company fundamentals and other insider activity when evaluating.